Status:
UNKNOWN
Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Conditions:
Prostaglandin E1
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
we hypothesized that periprocedural treatment with intravenous lipo-PGE1 may reduce myocardial injury and improve clinical outcomes in patients undergoing PCI.
Detailed Description
Ever since the inception of percutaneous coronary intervention (PCI), it has been apparent that some myocardial injury was often associated with the procedure, and even asymptomatic minor post-procedu...
Eligibility Criteria
Inclusion
- the presence of a non-ST-segment elevation acute coronary syndrome (unstable angina or non-ST-segment elevation acute myocardial infarction) sent to early PCI (within 72h of the onset of symptoms)
Exclusion
- a ST-segment elevation acute myocardial infarction, non-ST-segment elevation acute coronary syndrome with high-risk features warranting emergency invasive approach, left ventricular ejection fraction \<35%, previous revascularization, or renal failure with creatinine \>3 mg/dl
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01245855
Start Date
January 1 2011
End Date
December 1 2011
Last Update
November 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510080